Journal issues > Issue 3, March 2021 > O.11 Cyclin dependent kinase inhibitors (CDK4-6i) as adjuvant treatment for patients (pts) with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC): a systematic review and meta-analysis

O.11 Cyclin dependent kinase inhibitors (CDK4-6i) as adjuvant treatment for patients (pts) with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC): a systematic review and meta-analysis

By: Rafael Caparica , Elisa Agostinetto , Lucas Vian , Marco Bruzzone , Marcello Ceppi , Noam Ponde , Matteo Lambertini , Evandro de Azambuja

Introduction/aim: The combination of CDK4-6i and endocrine therapy (ET) is standard-of- care for pts with HR+/HER2- advanced breast cancer. However, studies evaluating adjuvant CDK4-6i provided contradictory results thus far. We conducted a systematic review and meta-analysis to assess if the addition of CDK4-6i to adjuvant ET impacts on survival’s outcomes and safety of pts with HR+/HER2- EBC.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top